ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学術雑誌論文等

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

https://hiroshima.repo.nii.ac.jp/records/2006506
https://hiroshima.repo.nii.ac.jp/records/2006506
887affc3-52af-40a7-9510-7893704ad68c
名前 / ファイル ライセンス アクション
bmcc_18_1231.pdf bmcc_18_1231.pdf (1004.7 KB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
言語 en
作成者 Tsutani, Yasuhiro

× Tsutani, Yasuhiro

en Tsutani, Yasuhiro

Search repository
Miyata, Yoshihiro

× Miyata, Yoshihiro

en Miyata, Yoshihiro

Search repository
Masuda, Takeshi

× Masuda, Takeshi

en Masuda, Takeshi

Search repository
Fujitaka, Kazunori

× Fujitaka, Kazunori

en Fujitaka, Kazunori

Search repository
Doi, Mihoko

× Doi, Mihoko

en Doi, Mihoko

Search repository
Awaya, Yoshikazu

× Awaya, Yoshikazu

en Awaya, Yoshikazu

Search repository
Kuyama, Shoichi

× Kuyama, Shoichi

en Kuyama, Shoichi

Search repository
Kitaguchi, Soichi

× Kitaguchi, Soichi

en Kitaguchi, Soichi

Search repository
Ueda, Kazuhiro

× Ueda, Kazuhiro

en Ueda, Kazuhiro

Search repository
Hattori, Noboru

× Hattori, Noboru

en Hattori, Noboru

Search repository
Okada, Morihito

× Okada, Morihito

en Okada, Morihito

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
権利情報 © The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
主題
主題Scheme NDC
主題 490
内容記述
内容記述 [BACKGROUND]:We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter phase II study. [METHODS]:Chemotherapy-naïve patient with stage IIIB-IV or recurrent nonsquamous NSCLC were eligible. We planned approximately four cycles of induction cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg) followed by maintenance with pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) until disease progression. Progression-free survival (PFS) was the primary endpoint. [RESULTS]:Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0-12.6), and overall survival was 48.0 (95% CI, 32.9-63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of 16 patients without EGFR mutations were 12.9 (95% CI, 9.4-16.3) and 7.9 (95% CI, 1.1-14.7) months, respectively. Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue (7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain (2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found. [CONCLUSIONS]:In patients with advanced or recurrent nonsquamous NSCLC, induction chemotherapy with cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and bevacizumab is safe and effective regardless of their EGFR mutation status.
言語 en
内容記述
内容記述タイプ Other
内容記述 This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
出版者
出版者 BioMed Central
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
関連情報
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s12885-018-5146-3
関連情報
識別子タイプ PMID
関連識別子 30526545
関連情報
識別子タイプ DOI
関連識別子 10.1186/s12885-018-5146-3
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1471-2407
開始ページ
開始ページ 1231
書誌情報 BMC Cancer
BMC Cancer

巻 18, p. 1231, 発行日 2018-12-10
旧ID 47067
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-21 03:23:26.615776
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3